• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1

tetano

Editor, Senior Moderator
PLoS Pathog


. 2024 Nov 11;20(11):e1012625.
doi: 10.1371/journal.ppat.1012625. eCollection 2024 Nov. Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1

Haodi Dong[SUP] 1 [/SUP], Runhong Zhou[SUP] 2 3 4 [/SUP], Jing Chen[SUP] 5 [/SUP], Jing Wei[SUP] 1 [/SUP], Zimeng Wei[SUP] 1 [/SUP], Ziqing Yang[SUP] 1 [/SUP], Kun Zhu[SUP] 1 [/SUP], Yufan Yang[SUP] 1 [/SUP], Qianqian Yang[SUP] 1 [/SUP], Na Liu[SUP] 2 [/SUP], Yuting Chen[SUP] 2 [/SUP], Yuhan Wu[SUP] 1 [/SUP], Yan Liang[SUP] 1 [/SUP], Yige Zeng[SUP] 1 [/SUP], Qile Guo[SUP] 1 [/SUP], Mingxi Li[SUP] 1 [/SUP], Sisi Shan[SUP] 1 [/SUP], Han Wang[SUP] 1 [/SUP], Mengyue Niu[SUP] 1 [/SUP], Isabella Yunfei Zeng[SUP] 6 [/SUP], Xuanling Shi[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Xinquan Wang[SUP] 5 [/SUP], Zhiwei Chen[SUP] 2 3 4 [/SUP], Linqi Zhang[SUP] 1 7 8 [/SUP]



Affiliations
Abstract

The ongoing evolution and immune escape of SARS-CoV-2, alongside the potential threat of SARS-CoV-1 and other sarbecoviruses, underscore the urgent need for effective strategies against their infection and transmission. This study highlights the discovery of nanobodies from immunized alpacas, which demonstrate exceptionally broad and potent neutralizing capabilities against the recently emerged and more divergent SARS-CoV-2 Omicron subvariants including JD.1.1, JN.1, KP.3, KP.3.1.1, as well as SARS-CoV-1 and coronaviruses from bats and pangolins utilizing receptor ACE2. Among these, Tnb04-1 emerges as the most broad and potent, binding to a conserved hydrophobic pocket in the spike's receptor-binding domain, distinct from the ACE2 binding site. This interaction disrupts the formation of a proteinase K-resistant core, crucial for viral-cell fusion. Notably, intranasal administration of Tnb04-1 in Syrian hamsters effectively prevented respiratory infection and transmission of the authentic Omicron XBB.1.5 subvariant. Thus, Thb04-1 holds promise in combating respiratory acquisition and transmission of diverse sarbecoviruses.


 
Back
Top Bottom